rituximab + CHOP
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
AIDS Related Lymphoma
Conditions
AIDS Related Lymphoma
Trial Timeline
Jan 1, 1999 → Oct 1, 2003
NCT ID
NCT00126243About rituximab + CHOP
rituximab + CHOP is a phase 2 stage product being developed by Roche for AIDS Related Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT00126243. Target conditions include AIDS Related Lymphoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00126243 | Phase 2 | Terminated |
Competing Products
20 competing products in AIDS Related Lymphoma